A Single Centre Experience with Phenotype Dependent Perioperative Chemotherapy for Primary Breast Cancer
| Autor: | Mária Mák, Adél Ambrus, Kofi Agyemang-Prempeh, Balázs Hillier, Ilona Laszip, Tamás Kullmann, István Sipőcz, Károly Kocsis, Tamás Pintér, Gabriella Herodek |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment medicine.disease Phenotype Carboplatin 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine Breast cancer Docetaxel chemistry Trastuzumab 030220 oncology & carcinogenesis Internal medicine medicine Primary breast cancer business neoplasms Adjuvant medicine.drug |
| Zdroj: | Journal of Cancer Therapy. 10:21-27 |
| ISSN: | 2151-1942 2151-1934 |
| Popis: | Background: Standard adjuvant or neo-adjuvant chemotherapy of primary breast cancers consists of docetaxel and the combination of anthracyclin-cyclophosphamide in two steps. According to international literature, the neo-adjuvant treatment of triple negative tumours by the combination of docetaxel-carboplatin allows a high rate of pathological complete remission and the adjuvant treatment of small, node negative HER2+ tumours by the combination of paclitaxel-trastuzumab allows a negligible recurrence rate together with a very good tolerance. Methods: Our aim was the retrospective analysis of the alternative chemotherapy regimens in our patient population. Results: The neo-adjuvant docetaxel-carboplatin allowed a 55% pathological complete remission rate among 20 patients. With the adjuvant paclitaxel-trastuzumab, we did not notice any recurrence among 5 patients at a median follow-up of 18 months. Conclusion: Our results correspond to the literature data. The spread of the protocols in the clinical practice is proposed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|